首页> 外文期刊>The Journal of Allergy and Clinical Immunology >IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma
【24h】

IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma

机译:IL-33促进重度类固醇抵抗性哮喘患儿的气道重塑

获取原文
获取原文并翻译 | 示例
           

摘要

Background: TH2 cytokines are not responsible for the ongoing symptoms and pathology in children with severe therapy-resistant asthma (STRA). IL-33 induces airway hyperresponsiveness, but its role in airway remodeling and steroid resistance is unknown. Objective: We sought to investigate the relationship between IL-33 and airway remodeling in pediatric patients with STRA. Methods: IL-33 levels were quantified in neonatal mice given inhaled house dust mite (HDM), and the effect of blocking IL-13 on remodeling and IL-33 levels was assessed. HDM-induced allergic airways disease (AAD) in neonatal ST2-/- mice lacking the IL-33 receptor was assessed, together with collagen production after IL-33 administration. The effect of steroid therapy on IL-33 levels in patients with neonatal AAD was explored. IL-33 expression was quantified in endobronchial biopsy (EB) specimens from children with STRA and related to remodeling, and collagen production by airway fibroblasts from pediatric patients stimulated with IL-33 and budesonide was quantified. Results: Blocking IL-13 after AAD was established in neonatal mice and did not reduce remodeling or IL-33 levels; airway hyperresponsiveness was only partially reduced. IL-33 promoted collagen synthesis both from asthmatic fibroblasts from pediatric patients and after intranasal administration in mice. Increased cellular expression of IL-33, but not IL-13, was associated with increased reticular basement membrane thickness in EB specimens from children with STRA, whereas remodeling was absent in HDM-exposed ST2-/- mice. IL-33 levels were maintained, whereas IL-13 levels were abrogated by steroid treatment in neonatal HDM-exposed mice and in EB specimens from children with STRA. Conclusion: IL-33 is a relatively steroid-resistant mediator that promotes airway remodeling in patients with STRA and is an important therapeutic target.
机译:背景:TH2细胞因子与严重治疗抵抗性哮喘(STRA)儿童的持续症状和病理无关。 IL-33诱导气道高反应性,但其在气道重塑和类固醇抵抗中的作用尚不清楚。目的:我们试图探讨小儿STRA患者IL-33与气道重塑之间的关系。方法:对吸入室内尘螨(HDM)的新生小鼠中的IL-33水平进行定量,并评估阻断IL-13对重塑和IL-33水平的影响。评估了在缺乏IL-33受体的新生ST2-/-小鼠中HDM引起的过敏性气道疾病(AAD),以及IL-33给药后胶原蛋白的产生。探索了类固醇疗法对新生儿AAD患者IL-33水平的影响。在患有STRA的儿童的支气管内活检(EB)标本中对IL-33的表达进行了定量分析,并与重塑有关,并对在IL-33和布地奈德刺激下的儿科患者气道成纤维细胞产生的胶原蛋白进行了定量。结果:在新生小鼠中建立AAD后阻断IL-13,并且不降低重塑或IL-33水平;气道高反应性仅部分降低。 IL-33促进了儿科患者的哮喘成纤维细胞和小鼠鼻内给药后胶原蛋白的合成。在STRA患儿的EB标本中,IL-33的细胞表达增加,但IL-13却不增加,这与网状基底膜厚度的增加有关,而HDM暴露的ST2-/-小鼠则没有重塑。维持了IL-33的水平,而在暴露于HDM的新生小鼠和患有STRA的儿童的EB标本中,通过类固醇治疗消除了IL-13的水平。结论:IL-33是一种相对抗类固醇的介质,可促进STRA患者的气道重塑,并且是重要的治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号